{"id":59096,"date":"2024-03-25T13:02:19","date_gmt":"2024-03-25T12:02:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-to-present-data-at-the-american-college-of-cardiology-annual-scientific-session-2024-reinforcing-extensive-body-of-evidence-in-clinical-and-real-world-settings-across-cardiovascul\/"},"modified":"2024-03-25T13:02:19","modified_gmt":"2024-03-25T12:02:19","slug":"bristol-myers-squibb-to-present-data-at-the-american-college-of-cardiology-annual-scientific-session-2024-reinforcing-extensive-body-of-evidence-in-clinical-and-real-world-settings-across-cardiovascul","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-to-present-data-at-the-american-college-of-cardiology-annual-scientific-session-2024-reinforcing-extensive-body-of-evidence-in-clinical-and-real-world-settings-across-cardiovascul\/","title":{"rendered":"Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio"},"content":{"rendered":"
\n

\nAnalysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF <50% in over 1500 patients, strengthening the safety profile of <\/i>CAMZYOS\u00ae<\/sup> <\/i>(mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy<\/i><\/b><\/p>\n

\nReal-world data reaffirm therapeutic value and treatment benefit of <\/i>CAMZYOS in improving cardiac symptoms and NYHA class in patients with obstructive hypertrophic cardiomyopathy<\/i><\/b><\/p>\n

PRINCETON, N.J.–(BUSINESS WIRE)–$BMY<\/a> #ACC<\/a>—Bristol Myers Squibb<\/a> (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6-8, 2024 in Atlanta, Georgia.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cThe therapeutic benefit of CAMZYOS in real-world practice, demonstrated by our data at ACC, builds on the well-established clinical program and further underscores the importance of this transformational medicine which is the first and only approved cardiac myosin inhibitor. With thousands of patients around the world treated to date, CAMZYOS is redefining the treatment landscape for this patient population and may offer hope to countless others moving forward,\u201d said Roland Chen, MD<\/a>, Senior Vice President and Head of Development, Immunology, Cardiovascular & Neurology. \u201cIn addition to showcasing our growing body of real-world evidence and safety data for CAMZYOS at ACC, we look forward to highlighting additional data from our cardiovascular portfolio, including an analysis of the real-world clinical impact of ELIQUIS.\u201d<\/p>\n

\nResearch to be presented at the meeting supports the robust safety and clinical profile of CAMZYOS\u00ae<\/sup><\/i> (mavacamten) and compliance with the Risk Evaluation and Mitigation Strategy (REMS) Program. These data include:<\/p>\n